Peripheral Vascular Interventions Market Size, Share and Global Trend By Procedure Type ( Angioplasty, Atherectomy, Others), By Implants (Stents, Catheters, Others), By End User (Hospitals, Ambulatory Surgery Centers, Others), and Regional Forecast, 2024-2032

Peripheral vascular intervention is a minimally invasive technique which is utilized to treat peripheral artery disease. Peripheral artery disease is caused due to building up plaque in arteries, which is also known as atherosclerosis. The important function of peripheral vascular intervention is to regularize blood flow to all parts of the body, including lower extremities to avoid amputations.

Certain causes such as smoking, diabetes, high cholesterol, and obesity are responsible for peripheral artery disease. According to National Heart, Lung and Blood Institute, an estimated 5.0% of population over 50 years suffer due to peripheral artery disease each year in the U.S. Also, according to Centres for Disease Control and Prevention, an estimated 8.5 million people in the U.S. are affected by peripheral artery disease, also 10.0-12.0% of the population is 50 years old. 

Benefits served by a peripheral vascular intervention such as enhanced safety, faster recovery, minimal hospital stays, and minimal procedural time are driving the global peripheral vascular intervention market. Also, the rising prevalence of peripheral artery disease is significantly driving the growth of the global peripheral vascular intervention market. Also, rise in certain risk factors such as obesity, smoking, high cholesterol, high blood pressure, and diabetes are prominently responsible for the rising prevalence of peripheral artery disease, which offers huge potential for mass adoption of peripheral vascular intervention procedures during the forecast period.

However, certain risk factors of peripheral vascular interventions such as allergic reaction, brain damage, infections, and strokes are restraining the global peripheral vascular intervention market.

Key Players Covered

Some of the key players present in the global peripheral vascular intervention market are Edwards Lifesciences Corporation, Cardinal Health, TERUMO CORPORATION, C. R. Bard, Inc., B. Braun Melsungen AG, Abbott, Boston Scientific Corporation, AngioScore Inc., Biotronik, Inc., Biosensors International Group, Ltd., Medtronic, and others.

SEGMENTATION

Among the segmentation of the global peripheral vascular intervention market, angioplasty from the procedure segment accounts for a larger share and is also anticipated to grow in the forecast period owing to its effective results in removal of coronary artery disease and also is a lower-risk option treatment.

Key Insights

• Prevalence of peripheral artery disease
• Reimbursement policies
• The regulatory scenario in key countries
• Key mergers and acquisitions

Regional Analysis

Geographically, the global peripheral vascular intervention market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global peripheral vascular intervention market in 2017 owing to an aging population, rising prevalence of peripheral artery disease, and rise in risk factors for peripheral artery diseases such as obesity and diabetes. Combined with this, certain advantages such as minimally invasive surgeries, minimal procedural time, and improved effectiveness of peripheral vascular intervention due to stenting procedures are driving the global peripheral vascular intervention market. The Asia Pacific and Middle East & Africa hold huge potential for global peripheral vascular intervention market owing to the rising geriatric population, rise in smoking, and the growing number of people with high cholesterol. Growth in adoption of advanced techniques in the healthcare sector and prevalence of the disease offers huge potential for adoption of peripheral vascular intervention procedures during the forecast period.

Key Industry Developments

• In April 2019, BIOTRONIK, Inc. launched CARNELIAN SUPPORT CATHETER designed to improve the access for treatment of highly calcified lesions in peripheral vasculature.
• In January 2019, Intact Vascular, Inc., announced the commercial use of TACK ENDOVASCULAR SYSTEM in Germany. It is the first-of-its kind of device for patients with peripheral artery disease
• In February 2018, Corindus, Inc., announced U.S FDA clearance of CORPATH GRX system for the use in peripheral vascular interventions. This system provides benefits of robotic precision and radiation protection.